Cyprotex Highlights - April 2020
Cyprotex will be joining speakers from Unilever, Proctor and Gamble, Humane Society International and Lhasa for a free webinar on ‘The Use of New Approach Methodologies for Cosmetic Safety Assessment without Animal Testing’.
Cyprotex's Head of Toxicology, Dr. Paul Walker, is presenting at the event on 'In Vitro Approaches to Cosmetic Safety Assessment'.
The event is hosted by ASCCT and ESTIV and is being held on Thursday, April 30, 2020 at 11:00 US ET / 16:00 BST / 17:00 CET.
Read our blog to learn more about our recent poster on 'Combined High Content Imaging in Liver Microtissues and Mitochondrial Toxicity to Predict Drug-Induced Liver Injury (DILI)' which was due to be presented at SOT 2020.
We are delighted to welcome our new Senior BD Director to the Cyprotex US team, Ralf Geiben Lynn.
Ralf holds a PhD in Biology from the Justus-Liebig University Giessen/Germany and an MBA from Boston University, and joins us with over 20 years experience in the life sciences industry. Previous roles have included Founder and C-Level positions in various start-up companies as well as Scientific Group Leader, Business Development and Business Advisory positions.
To arrange an introduction with Ralf, click on the link below.
Read Evotec’s latest white paper to learn more about Drug Abuse Liability Assessment including;
- why these studies are important for drugs which cross the blood-brain barrier
- when to perform these studies
- how these assessments are designed to meet regulatory testing requirements
- the benefits of an integrated approach
Read the latest news from parent company, Evotec:
- Evotec regain global development and commercialisation rights to iPSC-based programme for the treatment of diabetes
- Evotec enters strategic partnership with leon-nanodrugs to develop nanomedicines
- Just – Evotec Biologics develops humanoid antibody library (“HAL”) through AI-driven approach
- Evotec establishes gene therapy R&D site in Austria
- Evotec enters into multi-year gene therapy research alliance with Takeda
- Evotec signs licensing agreement with panCELLa to expand its iPSC-based cell therapy platform, EVOcells
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
enquiries@cyprotex.com